Protracted fecal shedding of HEV during ribavirin therapy predicts treatment relapse

Florence Abravanel; Sébastien Lhomme; Lionel Rostaing; Nassim Kamar; Jacques Izopet

doi:10.1093/cid/ciu742

Protracted fecal shedding of HEV during ribavirin therapy predicts treatment relapse

Clin Infect Dis. 2015 Jan 1;60(1):96-9. doi: 10.1093/cid/ciu742. Epub 2014 Sep 23.

Authors

Florence Abravanel¹, Sébastien Lhomme¹, Lionel Rostaing², Nassim Kamar², Jacques Izopet¹

Affiliations

¹ INSERM, U1043, Centre de Physiopathologie de Toulouse Purpan CHU Toulouse, Hôpital Purpan, Laboratoire de virologie, Centre National de Référence Hépatite E, Institut fédératif de biologie de Purpan.
² INSERM, U1043, Centre de Physiopathologie de Toulouse Purpan CHU Toulouse, Hôpital Rangueil, Service de Néphrologie, Dialyse et Transplantation multi-organe, France.

PMID: 25249523
DOI: 10.1093/cid/ciu742

Abstract

Twenty-four solid-organ-transplant recipients with chronic hepatitis E virus (HEV) infections were given ribavirin therapy for 3 months. All the patients with protracted fecal HEV shedding during treatment suffered a relapse. Monitoring HEV fecal excretion could be used to determine the optimal duration of ribavirin therapy.

Keywords: fecal shedding; hepatitis E virus; relapse; ribavirin therapy.

MeSH terms

Adult
Aged
Antiviral Agents / therapeutic use*
Feces / virology*
Female
Hepatitis E / drug therapy*
Hepatitis E / virology*
Hepatitis E virus / isolation & purification*
Humans
Male
Middle Aged
Organ Transplantation
Recurrence
Ribavirin / therapeutic use*
Treatment Outcome
Virus Shedding*

Substances

Antiviral Agents
Ribavirin